Prostate Cancer Roundtables
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
The panel discusses data from PEACE-3 and maintaining ARSI therapy with emerging combination treatments.
The experts discuss treatment selection in mHSPC and share insights from STOPCAP and ARANOTE on ARSI use in older patients.
The panel covers metastasis-directed therapy and trials including SWOG 1802 in oligometastatic prostate cancer.
The panelists examine biomarker adoption challenges and the impact of PSMA PET on staging and treatment decisions.
Experts discuss advances in biomarker testing, treatment intensification, and the impact of TALAPRO-2 in prostate cancer care
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
The panel exchanges strategies on sequencing and debates the potential of immunotherapy in prostate cancer.
In part four, the panel shares thoughts on the implications of recent trials including ARASENS, ARANOTE, and PEACE-3.
The panel discusses nuances to consider when using PSMA PET imaging, including differentiating false positives.
Experts discuss managing prostate cancer progression, risk stratification, and balancing treatment with quality of life.
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Part one of a roundtable series on prostate cancer, focusing on defining mHSPC and mCRPC.
The final segment of this roundtable series discusses radiopharmaceuticals and PARP inhibitors.
Part five of this roundtable series covers data and insights from the ARANOTE and PEACE 3 trials.
Part four of a PCa roundtable series focuses on the effectiveness of ADT with triplet therapy.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
The first part of this roundtable focuses on the impact of recent research on clinical practice.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer.
Experts review the CONTACT-02 trial as well as the Decipher score utilized in the STAMPEDE trial.
The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results.
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
Experts at ESMO 2024 discuss the implications and insights associated with the Peace III trial.
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.